Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Myers's"


2 mentions found


But J&J's drug is walking away with a notable edge over its rival. They add more options to a growing arsenal of treatments that have helped improve outcomes for people with multiple myeloma. But the new approvals also give J&J's therapy, which was developed with Legend Biotech, a clear advantage over Bristol Myers's drug. J&J's drug has gradually gained ground over Abecma in the CAR-T market for multiple myeloma, even though it first entered the market a year later. With the new approval on Friday, Jefferies' Shi expects J&J's drug to win the majority of that market share.
Persons: Jonathan Raa, Johnson, Myers's, Bristol Myers, Jefferies, Kelly Shi, Shi, Carvykti, Cantor Fitzgerald, Rick Bienkowski, Kelsey Goodwin, Annika, annikakim.constantino@nbcuni.com Organizations: Nurphoto, Bristol Myers Squibb, Johnson, Food and Drug Administration, FDA, Legend Biotech, Bristol, New York Stock Exchange, NYSE, Reuters, Mount Sinai Hospital, Getty Locations: Bristol, U.S, EU, Japan, Mount Sinai, New York City
Cohen said the privatization of public goods like education won't benefit the majority of Americans. Many fields that ordinary Americans assume to be public goods — public education, libraries, public transportation — don't fit that strict description. "In that definition, healthcare is a private good, not a public good," Cohen said. We're all familiar with the trickle-down claim that under a profit motive, business can provide public goods more efficiently than the government. "The alternative of private control over public goods is public control over public goods," he said.
Total: 2